PharmiWeb.com - Global Pharma News & Resources
19-Dec-2018

Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Insight Report 2018 - ResearchAndMarkets.com

The "Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

'Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Insight, 2018' report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Recurrent Head And Neck Cancer Squamous Cell Carcinoma development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products

4. Comparative Analysis

5. Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • Advaxis
  • Amgen Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals
  • Critical Outcome Technologies Inc.
  • Daiichi Sankyo Company
  • Genentech
  • Glycotope GmbH
  • Immunovative Therapies
  • Laboratoires Pierre Fabre SA
  • Mabion SA
  • MedImmune
  • Merck & Co.
  • Novartis AG
  • Oncolytics Biotech Inc.
  • Ono Pharmaceutical Co.
  • Panacea Biotec Limited

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/m52jnc/recurrent_head?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181219005683/en/

Editor Details

Last Updated: 19-Dec-2018